MRNA therapy takes on Hard-to-Treat multiple myeloma

NCT ID NCT07116616

Recruiting now Disease control Sponsor: ModernaTX, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study tests a new drug called mRNA-2808 in people with multiple myeloma that has returned or not responded to standard treatments. The drug is given through a vein and aims to control the cancer. The trial will check for side effects and measure how well the drug works. About 166 participants will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mRNA-2808
What this could lead to: If successful, this could provide a new treatment option for people with multiple myeloma that has not responded to other therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the treatment may not prove effective or safe. Side effects are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Atrium Health Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28204, United States
Emory University Hospital
RECRUITING

Atlanta, Georgia, 30322, United States
Mass General Brigham
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan-Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Penn Medicine
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
The Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Tisch Cancer Institute at Mount Sinai
RECRUITING

New York, New York, 10029, United States
UCSF
RECRUITING

San Francisco, California, 94143, United States
University of Alabama at Birmingham Hospital
RECRUITING

Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.